Arrhythmogenic cardiomyopathy (AC) is an inherited heart muscle disease associated with point mutations in genes encoding for cardiac desmosome proteins. Conventional mutation screening is positive in ≈50% of probands. Copy number variations (CNVs) have recently been linked to AC pointing to the need to determine the prevalence of CNVs in desmosomal genes and to evaluate disease penetrance by cosegregation analysis in family members.
A rrhythmogenic cardiomyopathy (AC) is an inherited heart muscle disease characterized by progressive fibro-fatty replacement of the ventricular myocardium. [1] [2] [3] The structural alterations are responsible for electric abnormalities which may lead to malignant ventricular arrhythmias and sudden cardiac death, particularly in young people and athletes. 4, 5 The prevalence of the disease in the general population is estimated to be between 1:2000 and 1:5000, and men are affected more frequently than women, with a ratio of 3:1. AC is mostly inherited as an autosomal dominant trait with incomplete penetrance and variable phenotypic expression. 6 Point mutations have been described in genes encoding desmosomal proteins, such as plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2), and desmocollin-2 (DSC2), which forms a cell membrane structure essential to provide mechanical and functional integrity to adjacent cardiomyocytes. 7, 8 Genomic structural variations, ranging in size from kilobases (kb) to megabases (Mb), are not identifiable by conventional chromosomal banding (ie, chromosome analysis, fluorescent in situ hybridization, loss of heterozygosity assays, etc) or mutational screening (ie, denaturing high performance liquid chromatography, Sanger sequencing, etc). These changes (deletions, duplications, and insertions) have been referred to copy number variations (CNVs).
Conventional mutation screening in desmosomal genes fails to detect causative mutations in ≈50% of AC index cases, thus the evaluation of CNVs was advocated. 9 In the present study, we assessed the prevalence of large genomic rearrangements in desmosomal genes in 160 AC probands who were negative for
WHAT IS KNOWN?
• Conventional mutation screening in desmosomal genes is performed as gold-standard to identify point mutations (single/few nucleotide variations) in patients affected by arrhythmogenic cardiomyopathy (AC).
• Conventional mutation screening detects mutations in ≈50% of AC probands, pointing to the need to identify novel genetic substrates in genotype-negative AC families.
• Copy number variations (deletions, duplications, and insertions sized from kilobases to megabases) have been recently described in AC, but their clinical meaning and prevalence remain to be elucidated.
WHAT THE STUDY ADDS?
• Copy number variations can escape detection by conventional mutation screening, thus routine clinical genetic testing should expand to include copy number variation screening.
• Identification of 2 new large deletions/duplications in desmosomal cadherin genes is reported for the first time, providing further evidence of the underestimated prevalence of copy number variations in patients with AC and the need of extensive cascade evaluations of family members. • In our series, 7% of genotype-negative AC probands harbor an extensive PKP2 or desmosomal cadherin gene heterozygous deletion, increasing significantly the diagnostic yield of genetic testing and highlighting molecular genetics complexity in AC.
• Heterozygous complete gene elimination of the PKP2, DSG2, and DSC2 alleles results in a penetrance of ≈30%, suggesting that multigenic modifiers underlie the variable disease expression. 
MATERIALS AND METHODS

Study Population and Clinical Evaluation
The study included 160 unrelated index patients of Italian descent diagnosed with AC according to revised criteria established by the 2010 Task Force 10 and negative for pathogenic point mutations in PKP2, DSP, DSG2, DSC2, and JUP genes at conventional genetic testing methods. Pathogenicity of genetic variants was determined based on allelic frequency in multiethnic large international exome and genome control sequencing data sets (ie, National Heart, Lung and Blood Institute Exome Variant Server, 1000 Genomes Project, Exome Aggregation Consortium), location within functional domains of previously reported genes associated with disease susceptibility, and analysis by in silico prediction algorithms (ie, Sorting Intolerant From Tolerant, Polymorphism Phenotyping, Mutation Taster). Specifically, minor allele frequency threshold was set to <0.02% as to reflect AC prevalence range of 1:2000 to 1:5000 (allelic frequency, 0.02%-0.05%). Clinical evaluation consisted of a detailed personal and family history, physical examination, 12-lead ECG, 2-dimensional echocardiogram, signal-averaged ECG, and stress test ECG. 6 Contrast-enhanced cardiac magnetic resonance was performed according to previously reported methods in selected cases. 11 Available family members carrying CNVs in desmosomal genes were also clinically evaluated. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. The study protocol was approved by the ethics committee review board of the University of Padua (Padua, Italy). All the participants provided written informed consent before inclusion in the study.
Evaluation of Desmosomal Genes Copy Number
The presence of CNVs in desmosomal genes was investigated by multiplex ligation-dependent probe amplification (MLPA) using the SALSA MLPA P168 ARVC-PKP2 probemix (MRCHolland, The Netherlands) that contains 16 probes for each exon of PKP2 gene, including its promoter, 6 probes for DSP (on exons 1, 5, 7, 9, 21, 24); 3 probes each for JUP (on exons 2, 9, 12), DSC2 (on exons 1, 7, 17), DSG2 (on exons 1, 6, 15), and TGFβ3 (on exons 1, 6, 7); 2 for RYR2 (on exons 3, 97) and 8 reference probes. The probes used for DSP, JUP, DSC2, DSG2, TGFβ3, and RYR2 genes do not cover 90%, 79%, 83% 88%, 47%, and 98% of the coding regions, respectively.
MLPA was performed according to manufacturer's protocol: 12 hours hybridization of the probes on 100 ng of denatured genomic DNA at 60°C, sample incubation with Ligase-65 enzyme at 54°C for 15 minutes, amplification of the ligated probes in a multiplex polymerase chain reaction (PCR), and capillary electrophoresis separation of fluorescein amidite-labeled MLPA amplification products on an ABI3500 Dx Genetic Analyzer (Life Technologies-Applied Biosystems, Massachusetts). One control every 7 samples was included in each MLPA reaction. Deletions/duplications were confirmed by 2 independent experiments. Data were analyzed by the GeneMapper v3.1 software (Applied Biosystems) and then exported to the Coffalyser (v1.0.0.43) software (MRCHolland) for statistical and quantitative analyses. Ratios of 0.4 to 0.6 and >1.4 were considered evidence of deletion and duplication, respectively, while a ratio of 0.75 to 1.25 was considered to be normal by MLPA.
Quantitative PCR Validation
Identified deletions/duplications were further confirmed by quantitative real-time PCR. Quantitative PCR experiments were performed with the GoTaqPCR Master Mix containing a Carboxy-X-rhodamine passive reference dye (Promega, Wisconsin) in an ABI PRISM 7900HT Sequence Detector (Applied Biosystems) as reported previously. 12 Briefly, all samples were tested in duplicate in MicroAmp 96-well reaction plate sealed with an optical adhesive film (Applied Biosystems) with 10 ng of DNA template, a final concentration of 300 nmol/L for both forward and reverse primers ( Table  I in 
RNA Deletion Analysis of PKP2 Exon 4
RNA was isolated from whole blood on a Magna Pure Compact workstation (Roche Applied Science, Germany) by using RNA Isolation kit I.
Reverse transcription was performed using random examers and Superscript III reverse transcriptase (Life Technologies) according to manufacturer's protocol. PCR spanning exon 4 was performed using the following primers, located on exons 3 and 5 of PKP2: F 5′-agcccgtcactcagaacag-3′, R 5′-atgccacgaagctggtta-3′. Reverse transcription PCR products were size separated by agarose gel electrophoresis, gel isolated, and directly sequenced on an ABI 3500 Dx and analyzed with LaserGene SeqManPro (DNASTAR, Wisconsin) and AlaMut software (version 2.9, Interactive Biosoftware, Rouen, France).
Haplotype Analysis
To establish whether the rearrangements involving all the PKP2 genomic sequence observed in 5 apparently unrelated subjects could be ascribed to the same mutational event or arose independently, we evaluated 7 microsatellite markers spanning a region of ≈2.3 Mb across the PKP2 locus. In addition, these markers were used for genotyping an additional subject carrying a 122-kb deletion in chromosome 12 encompassing the entire PKP2 gene who came to our attention because of this deletion but without any clinical signs of the 
Characterization of PKP2 Deletion Breakpoint
Fine mapping of the PKP2 deletion breakpoints, previously defined by high-density single-nucleotide polymorphism arrays (13) , was performed by PCR with primers designed to anneal deletion's flanking regions: F 5′-tgtgaaaatgaccagctatttaagtt -3′ and R 5′-ggattagtcctcttgggaatgt -3′. The purified PCR product was directly sequenced.
Massive Parallel Sequencing
To exclude the presence of point mutations in other AC genes, all 11 index cases carrying CNVs underwent massive parallel sequencing on a MiSeq platform (Illumina, San Diego, CA) by using TruSight Cardio Kit sequencing panel which comprises 174 cardiac-related genes (http://www.illumina.com/products/trusight-cardio.html). Library preparation and sequencing were performed according to the manufacturer's instructions (Illumina). Data analysis was performed by using VariantStudio software (Illumina) and AlaMut software (Interactive Biosoftware).
For the purpose of the study, rare variants definition with minor allele frequency ≤1% is inadequate assuming that the estimated AC prevalence is ≈1:5000, thus only rare genetic variants with minor allele frequency <0.02% expected to affect the protein sequence of disease-related genes are reported in Table II in the Data Supplement.
Statistical Analysis
Data are expressed as mean±SD and were analyzed using SPSS version 22 (IBM SPSS, Inc, Chicago, IL). Descriptive analyses were performed for all participants. Comparisons were performed by univariate models using independent samples t tests for continuous variables and χ 2 tests for categorical variables as appropriate. A value of P<0.05 was considered significant.
RESULTS
Intragenic Deletion/Duplication Analysis of the Desmosomal Protein-Encoding Genes
In a cohort of 160 patients with AC lacking other pathogenic point mutations in AC-related desmosomal genes, we identified 11 probands (6.9%, 10 males, mean age 35±18 years) carrying CNVs; 9 in PKP2 and 2 in cardiac cadherin-encoding genes (Table 1) .
Of the 9 heterozygous PKP2 CNVs carriers, 5 encompassed deletion of all PKP2 exons while 4 carried a single-or multiple-exon deletion/duplication of PKP2 gene (specifically, 2 probands had a deletion of PKP2 exon 4 only, 1 with a PKP2 deletion comprising exons 6-11 and 1 with a PKP2 genomic duplication involving the 5′ untranslated region till exon 1).
Of the remaining 2 cardiac cadherin-related gene CNV carriers, 1 had a duplication of at least DSC2 exons Figure 1A) .
Isolation of RNA from patient blood cells followed by reverse transcription and PCR amplification of selected fragments showed that the patients carrying the PKP2 exon 4 deletion (F-III,5; G-I,1) lack a specific region of 44 bp from PKP2 mRNA, corresponding to exon 4 (Figure 1B) . Haplotype analysis suggested that independent mutational events occurred in these 2 probands (data not shown).
Clinical Findings of Probands Carrying CNVs in the PKP2 and Cadherin-Encoding Genes
Clinical features of 11 index cases are summarized in Table 1 (examples in Figures 2 and 3) . Identification of the CNVs was not considered as a criterion to reach AC diagnosis.
Clinical follow-up ranged from 2 to 36 years (mean, 13.7 years). All subjects were treated with antiarrhythmic therapy (4 with β-blockers, 4 with sotalol, 1 with flecainide, 1 with amiodarone plus β-blocker, and 1 with propafenone plus sotalol). Moreover, 8 of the 11 patients received an implantable cardioverter defibrillator.
Cascade Genetic Screening and Clinical Features in Family Members Carrying CNVs
Cascade genetic screening of the 56 family members identified 31 subjects (18 women, 13 men, mean age 42±18 years) carrying a PKP2 or other cadherin- related CNVs (Figure 4 ). Of these, 19 (11 women, 8 men, mean age 41±20 years) were heterozygous for the complete PKP2 deletion, 11 (6 females, mean age 45±20 years) were heterozygous for single/multiple PKP2 exon deletions/duplication, and 1 was heterozygous for the chromosome 18q large deletion. Of note, the absence of the partial DSC2 duplication in the parents' proband indicated a de novo mutation with ambiguous pathogenicity because the mother, in whom the DSC2 duplication is absent, was diagnosed based on 1 major and 3 minor disease criteria. Among 31 family members carrying a CNV, 3 were not avail- Table 2 . The identification of a CNV was not considered as a criterion to reach AC diagnosis; however, family history was counted as a major AC criterion according to the 2010 Task Force criteria. Overall, disease penetrance was 32% in relatives carrying CNVs undergoing familial evaluation. The age at diagnosis of relatives fulfilling diagnostic criteria did not differ significantly from that at last evaluation of subjects not fulfilling diagnostic criteria (39±18 versus 43±18 years; P=NS). Moreover, among relatives fulfilling diagnostic criteria, men resulted to be significantly more often affected than women (53% versus 16.6%; P=0.05).
AC Penetrance in Entire PKP2 Gene Deletion Carriers
A total of 24 subjects carried the same deletion encompassing the entire PKP2 gene.
Among the 5 probands (all males, mean age at diagnosis 34±13 years), 3 showed sustained ventricular arrhythmias, 4 received an implantable cardioverter defibrillator, and 1 had left ventricle involvement.
Clinical evaluation of the 19 family members (12 females) revealed that 8 (42%, 5 men, 3 women) fulfilled diagnostic Task Force criteria while 3 (1.6%, 1 man, 2 women) had borderline diagnosis. The remaining 8 family members carrying the complete PKP2 gene deletion had no signs of the disease, during a mean follow-up period of 6±5 years. Phenotype-negative carriers had a similar age compared with other affected family members (43±20 versus 41±20 years; P=NS).
Overall, disease penetrance was 42% in relatives undergoing familial evaluation. Among mutation carriers, men resulted to be more often affected than women (71% versus 25.5%; P=0.07).
DISCUSSION
Herein, we report for the first time the identification of 2 new large deletions/duplications in desmosomal cadherin genes, as well as extensive PKP2 heterozygous deletions in 7% of genotype-negative AC probands, providing further evidence of the underestimated prevalence of CNVs in patients with AC. After the first application of MLPA to detect CNVs of BRCA1 gene involved in hereditary disposition for breast cancer, 12 this technique was applied in a variety of genetic disorders to identify October 2017 8 medium-large deletions/duplications not detectable by conventional mutation screening or cytogenetic techniques. Although recent studies described the involvement of rare CNVs in inherited cardiomyopathies, the contribution of these CNVs to the disease phenotype development remains elusive and depends mainly on whether dosage-sensitive genes or regulatory sequences are affected by the genomic rearrangement.
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CNVs in Primary Cardiomyopathies
The first application of MLPA in cardiogenetics was performed in a series of mutation-negative long-QT syndrome probands, resulting in the identification of a 3.7-kb KCNH2 duplication expected to decrease the rapidly activated delayed rectifier potassium current (Ikr). 14 Furthermore, studies reported KCNH2 deletions and demonstrated that genomic rearrangements in KCNQ1 and KCNH2 explain 3% of the long-QT syndrome cases in which no point mutations in disease-related genes were found. 15, 16 In the setting of structural cardiomyopathies, a 3.5-kb deletion including exons 28 to 35 was reported in MYBPC3 in a cohort of 100 patients with hypertrophic cardiomyopathy, 17 showing that large genomic rearrangements contribute also to hypertrophic cardiomyopathy (estimated prevalence <1%). The contribution of CNVs was also demonstrated for dilated cardiomyopathy, specifically in lamin A/C and BAG3 genes.
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CNVs in AC
Large deletions in PKP2 gene, one of the major causative AC-related genes, were previously described by other 4 independent genetic studies implying a pathogenic role of this CNV in the disease because of haploinsufficiency.
9,21-23 First, Cox et al 9 described 3 large PKP2 deletions in a 149 Dutch AC cases, reporting an estimated prevalence of PKP2-related CNVs of ≈2%. The authors highlighted the importance of performing additional analysis in search of CNVs and advocated the possibility of large deletions in other desmosomal genes. Indeed in our study, the estimated prevalence of PKP2-related CNVs was 5.6% (9 of the 160) in genotype-negative probands, probably because of the founder effect of the deletion encompassing the entire coding region of the gene. Moreover, we report for the first time CNVs in desmosomal cadherin-related genes (DSG2, DSC2): a de novo duplication of DSC2 exons 7 to 9 in a 18-year-old patient with definite AC criteria which did not segregated with the disease and a 482-kb deletion in chromosome 18q encompassing all desmogleins and desmocollins isoforms (exception made for DSC3) in a 15-year-old patient with a massive form of biventricular AC. A wide clinical spectrum was observed in the 32 family carriers with complete/partial PKP2 or other desmosomal cadherins deletions/duplications. The reduced penetrance of the disease in family carriers (≈32%) is similar to the one observed in other point mutations and emphasizes the role of other factors in the development and progression of the disease. Age-related penetrance alone cannot explain this clinical variability because in our study the age at diagnosis did not differ from that of clinically unaffected patients at last evaluation. Finally, similarly to previous reports, males resulted to be more often affected than females mutation carriers. Later, Roberts et al 21 reported another 2 PKP2 CNV carriers. A 35-year-old man without family history of sudden death who showed a sustained ventricular tachycardia originating from the right ventricle outflow tract, ECG abnormalities, and normal cardiac magnetic resonance, carrying a 112-kb PKP2 deletion. And a second case who was a 20-year-old man with definite AC diagnosis and a mild developmental delay carrying a de novo 7.9 Mb deletion of chromosome 12p12.1p11.1, which encompassed the entire PKP2 gene. 21 Cardiac evaluation demonstrated ECG alterations, late potentials and premature ventricular beats, even if cardiac magnetic resonance of these subjects was normal. The deletion of 12p has been often associated with developmental delay, mental retardation, and craniofacial abnormalities; however, it is intriguing to understand how a PKP2 deletion leads to additional features, such as left ventricular noncompaction, Brugada syndrome, dilated cardiomyopathy, and AC. 24 In our clinical center, we also evaluated a 44-year-old subject with complete PKP2 deletion without family history of AC or sudden death and absence of AC criteria during cardiological screening. She came to our attention after her 4-yearold daughter affected by agenesis of the corpus callosum and epilepsy, was found to have a 122 kb deletion on chromosome 12, encompassing PKP2. This case was not included in our cohort of AC probands but supports the theory of PKP2 involvement in developmental anomalies and further emphasizes that PKP2 haploinsufficiency alone may not lead to AC phenotype.
Furthermore, another patient with a severe form of AC and no family history of heart disease or sudden cardiac death was reported by Sonoda et al 23 carrying a heterozygous deletion of at least 1.23 Mb on chromosome 12p11-12, which included PKP2, SYT10, and ALG10 genes. This study, together with the recent description of a French family 25 in which only PKP2 homozygous gene deletion carriers show left ventricular noncompaction whereas heterozygous family member carriers were completely asymptomatic, is in keeping with the concept that PKP2 haploinsufficiency may have various effects on disease development and progression as other desmosome-related point mutations. The incomplete penetrance of AC might be explained by a recessive-like inheritance pattern, as already demonstrated for point mutations. In fact, homozygous, compound heterozygous, digenic/oligogenic variants, or combination genetic and exogenetic factors in desmosomal genes are frequently described in patients with AC. 3, [26] [27] [28] Noteworthy, in our study, the proband carrying the 482 kb CNV on chromosome 18q (family K) had also a DSC2 missense variant previously reported as pathogenic only in homozygous state 29 ; and the DSC2 duplication (family J) was not segregating with the disease in the affected family member.
Overall, our and literature data are in keeping with the concept of a broad modifier effect, ranging from early onset to lack of segregation and reduced penetrance. Gene dosage effects that may occur because of deletions, duplications, and loss-of-function mutations and underlie oligo-and multigenic inheritance have been confirmed also in experimental models for AC. 30, 31 Stoichiometric alterations of macromolecular complexes (and cellular networks) or a combination of innocent single mutations at 2 loci encoding interacting proteins may lead to a fitness defect. Thus, special attention should be paid to variants appearing in genes encoding subunits of the same macromolecular complexes or involved in the same biological pathways because they might contribute to the phenotypic variability. This is reflected in the idea that the combination of mutations in several loci leads to increased risk of having an overt AC phenotype. [26] [27] [28] This phenomenon has been also described in other cardiomyopathies as to demonstrate that these rare cardiac disorders with low/absent disease penetrance, previously considered monogenic, may be the result of the cumulative effect of more loci (risk alleles) suggesting a more complex inheritance model.
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Implications for Genetic Testing
Our findings support the idea that the mutational yield of CNVs in AC increased further the diagnostic potential of genetic testing, thus routine clinical genetic testing should expand to include screening of CNVs. Besides PKP2, the limited number of probes used in all other genes resulted in incomplete coverage of structural variations, explaining why PKP2 CNVs were more frequently identified. However, it is also worth noting that structural variation data are limited in control groups, thus should be interpreted with caution. This is particularly true for PKP2 complete gene deletion because several family members carrying CNV were phenotypically negative.
Compared with lower-throughput Sanger sequencing, analysis of MPS data allows detection of complex genomic rearrangements relying on bioinformatics algorithms for automated variant calling. 33 Thus, MPS has the potential to evolve in a more efficient diagnostic tool although bioinformatics troubleshooting needs still to be solved. 34 The lack of publicly available data sets on structural variants and to annotate rare CNVs makes difficult the interpretation of CNVs in the clinical setting. Functional studies and family cosegregation analysis are mandatory to provide an insight into the role of these mutations in the disease pathogenesis and to establish a proper genotype-phenotype correlation. This aspect will be further enhanced by the tremendous growth of MPS and omics data, thus caution must be paid in interpretation of point mutations and CNVs as disease related. 
AFFILIATIONS
